CIRON

CIRON offers products of International Standards and keep strict control over quality and productivity at every stage. Our congenial environment; well built infrastructure; energetic & highly competent technical staff and workforce; unique human relationship; efficient & committed management support are the pillar to practice up-to-date Quality Management Systems and thus results in meeting highest quality standards, safety and productivity. We also produce and export a number of products in the brand name beside the generic formulations. Our branded pharmaceutical formulations enjoy steady demand in following countries: Asia: Philippines, Vietnam, Srilanka, Indonesia, Malaysia, Cambodia, Iraq and Papua New Guinea. Africa: Uganda, Nigeria, Ghana, Malawi, Zambia, Kenya, Mozambique, Mauritius, Madagascar, Angola and Guinea, etc. Latin & Central America: Costa Rica, Honduras, Nicaragua, Puerto Rico, Dominican Republic, Guatemala, Guyana, Peru, Bolivia, Venezuela and others. Europe & USA for re-export to under developed and developing Nations: Belgium, Germany and USA. The CIRON Group's strong manufacturing competence, its committed team and its continuous pursuit of total quality are all focused on further expanding CIRONS large base of satisfied clients and fulfilling its objective of becoming a world leader in formulations for the pharmaceutical industry. The Ciron Group is committed to build a mutually beneficial business relationship with both national and international customers. Importers, distributors and agents who can introduce Ciron products in their national markets are warmly invited to contact the company. We are looking for franchising in national and international markets. The formulation (drug in a ready-to-consume form such as tablet) in the generic market is being as Abbreviated New Drug Application (ANDA). It is called ANDA because the generic manufacturer does not have to go through the elaborate clinical trials that the original patent-holder would have to go through. Since the properties of the drug are already known, the trials for generics are limited when compared to a new drug. The US regulatory authority looks at aspects such as bioequivalence (the rate at which the drug is absorbed in the bloodstream) when granting approval to a generic formulation. This is to make sure that the generic drug performs with the same effectiveness as the branded drug in the human body. ANDA approvals are not an easy affair. The costs and delays are a factor to reckon with. As in the case of the bulk drugs, the manufacturing facilities have to be approved by the US regulatory authorities.